Baneocin powder for skin 10g — Made in Austria — Free Delivery

Pharmacological properties

Pharmacodynamics. Baneocin is a combined antibacterial preparation for external use, containing two bactericidal antibiotics with a synergistic effect. Bacitracin is a polypeptide antibiotic, active against gram-positive microorganisms, such as hemolytic streptococcus, staphylococcus, clostridium spp., corynebacterium diphtheriae, treponema pallidum, as well as against some gram-negative pathogens such as neisseria spp. and haemophilus influenzae. the spectrum of action of the preparation also includes actinomycetes and fusobacteria. strains resistant to bacitracin are rare.

Neomycin is active against gram-positive and gram-negative microorganisms, such as staphylococci, Proteus, Enterobacter aerogenes, Klebsiella pneumoniae, Salmonellae, Shigellae, Haemophilus influenzae, Pasteurella, Neisseria meningitidis, Bibrio cholerachus, Cuscalis, Bibrio cholerae, Bordetetella, faptoecillus Escherichia coli, Mycobacterium tuberculosis, Borrelia and Leptospira interrogans (L. icterohaemorrhagicae).

The combined use of bacitracin and neomycin provides a broad antimicrobial spectrum, but the preparation is inactive against Pseudomonas, Nocardia spp., Fungi and viruses.

Usually, bacitracin and neomycin are not prescribed systemically. Topical application of Baneocin ointment and powder significantly reduces the risk of developing sensitization characteristic of systemic antibiotics.

Pharmacokinetics. Baneocin is well tolerated. Since the absorption of bacitracin and neomycin through the affected skin is negligible, the Cmax of the preparation is achieved at the site of application. Tissue tolerance is excellent, the preparation is not inactivated by tissues, blood and other biological fluids. If the preparation is applied to large affected areas of the skin, you should remember about the possibility of absorption of the preparation and its consequences (see SIDE EFFECTS, SPECIAL INSTRUCTIONS).

When used correctly, Baneocin exhibits a local effect at the site of application. If absorption of active substances occurs, T½ of neomycin and bacitracin in blood serum is about 2-3 hours.

Bacitracin is slightly absorbed through the mucous membrane and skin. However, absorption through the skin is possible in the presence of open wounds.

Minimal amounts of neomycin are absorbed through intact skin. Through inflammatory or affected skin and in the absence of a keratin layer (ulcers, wounds, burns), neomycin is rapidly absorbed.

Indications

Ointment. local treatment and prevention of bacterial skin infections caused by microorganisms sensitive to the preparation:

boil, carbuncle (after surgery), abscess (after opening), sycosis, including deep in the chin area, purulent hydradenitis, pseudofurunculosis, paronychia;

limited degree bacterial skin infections, including contagious impetigo, infected varicose ulcers, secondary infections with eczema, infections with burns, after cosmetic surgery and skin transplantation (also for prophylactic purposes and with the use of dressings);

as an adjunct therapy for infected wounds (for example, with otitis externa, secondary infection of surgical scars).

Powder. Bacterial infections of limited skin areas: bacterially infected herpes simplex, herpes zoster / chickenpox; contagious impetigo; infected varicose ulcers; infected eczema; bacterially infected diaper dermatitis.

Prevention of umbilical infection in newborns.

As adjunctive therapy:

• after surgical (dermatological) manipulations (including after excision and cauterization);
• with cracks in the skin;
• with ruptures of the perineum, episiotomy;
• with wound eroded surfaces (with exudate).

Application

Ointment: for adults and children, baneocin ointment should be used usually 2-3 times a day for 7 days.

When applied topically for more than 7 days, the dose of neomycin should not exceed 1 g / day (equivalent to 200 g of ointment). With a repeated course, the maximum dose should be reduced by 2 times.

Apply a small amount of ointment to the affected area and rub it lightly. If necessary, after applying the preparation, a gauze bandage can be applied to the affected area.

Powder: for adults and children from birth, Baneocin powder is usually used 2–4 times a day.

After applying the powder to the affected areas of the skin, the natural process of evaporation (sweating) is activated, therefore the preparation has a cooling, soothing effect.

Spread the powder over the surface to be treated. If necessary, after applying the preparation, a gauze bandage can be applied to the affected area.

For patients with burns occupying more than 20% of the body surface, use Baneocin powder no more than 1 time per day, especially in case of impaired renal function, since the absorption of the active substances of the preparation is possible.

When applied topically, the dose of neomycin should not exceed 1 g / day (equivalent to 200 g of powder) for more than 7 days. With a repeated course, the maximum dose should be reduced by 2 times.

Contraindications

Hypersensitivity to preparation components or other aminoglycoside antibiotics.

Extensive and severe skin lesions (possible resorption of the preparation with the development of an ototoxic effect with hearing loss).

If uncontrolled absorption of the preparation is likely, it should not be used in patients with severe cardiogenic or nephrogenic excretory disorders, as well as in the presence of a history of lesions of the vestibular and cochlear systems. The preparation should not be injected into the external auditory canal with perforation of the tympanic membrane. Do not apply to the area around the eyes.

Side effects

The frequency of adverse reactions is defined as follows: very often (? 1/10), often (? 1/100, 1/10), infrequently (? 1/1000, 1/100), rarely (? 1/10 000, 1 / 1000), very rare (1/10 000), frequency unknown (cannot be calculated from the available data).

Usually, when applied externally, the preparation is well tolerated.

On the part of the immune system: rarely - in the presence of allergic reactions to neomycin, cross-allergy to other aminoglycoside antibiotics also occurs in about 50% of cases; the frequency is unknown - hypersensitivity to neomycin and many other substances may occur if the preparation is used for chronic dermatosis or chronic otitis media. Under certain circumstances, allergies can manifest as a lack of successful wound healing.

From the nervous system: unknown - damage to the vestibular nerve, neuromuscular blockade.

From the organ of hearing and labyrinth: frequency unknown - ototoxicity.

On the part of the skin and subcutaneous tissue: rarely - allergic reactions, manifested mainly as contact dermatitis. Allergic reactions caused by neomycin are not as common as it is generally believed; the frequency is unknown - in case of prolonged use, allergic reactions such as redness, dryness and flaking of the skin, rash, itching may occur. Spread of lesions or lack of healing can be caused by allergies. Photosensitization or phototoxic reactions by exposure to sunlight or UV radiation cannot be ruled out.

On the part of the kidneys and urinary tract: the frequency is unknown - nephrotoxicity.

Special instructions

When using the preparation in patients with extensive skin lesions, one should take into account the possibility of absorption of the active components of baneocin and, as a consequence, the development of oto- and / or nephrotoxic effects. since the risk of developing toxic effects increases in patients with severe hepatic and / or renal impairment, such patients should undergo urine, blood tests, audiometric studies before and during intensive therapy with baneocin. it is required to observe precautions for prolonged use in patients with chronic otitis media due to the possible ototoxic effect.

The combination of systemic and local aminoglycosides should be avoided due to the risk of cumulative toxicity.

If uncontrolled absorption of Baneocin occurs, it is necessary to take into account the possibility of developing a blockade of neuromuscular conduction, especially in patients with acidosis, a history of severe myasthenia gravis (Myasthenia gravis), or with other neuromuscular disorders. The neuromuscular blockade is eliminated with calcium supplements or neostigmine.

With prolonged treatment, excessive growth of resistant microorganisms and fungi is possible. In this case, appropriate treatment should be prescribed.

Patients who have developed an allergy or superinfection, the preparation must be canceled.

Contact with sunlight or UV rays may cause phototoxic reactions or photosensitization.

The ointment contains the auxiliary substance lanolin, which can cause local skin reactions (eg contact dermatitis).

Use during pregnancy and lactation. If there is a risk of absorption of active substances during pregnancy and lactation, the preparation is used only if the expected benefit to the mother outweighs the potential risk to the fetus or child.

Like other aminoglycoside antibiotics, neomycin crosses the placental barrier. There have been reports of fetal hearing impairment due to the systemic use of high doses of aminoglycosides.

Before breastfeeding, it is necessary to remove the remnants of the preparation from the mammary gland with boiled water and sterile cotton wool.

Children

Powder: used from the first days of life as prescribed by a doctor after a careful assessment of the benefit / risk ratio.

Ointment: there is not enough data on the safety of using the preparation in the indicated dosage form in young children, therefore, the use of the preparation in children is possible as prescribed by a doctor after a careful assessment of the benefit / risk ratio.

The ability to influence the reaction rate when driving or working with other mechanisms. Unknown.

Interactions

If systemic absorption is detected, with the simultaneous use of cephalosporins or aminoglycoside antibiotics, the risk of developing nephrotoxic reactions increases.

The simultaneous use of diuretics such as ethacrynic acid or furosemide can increase the severity of oto- or nephrotoxicity.

In the case of systemic absorption, when combined with opioid analgesics, analgesics or muscle relaxants, the risk of developing neuromuscular conduction disorders increases.

Overdose

When used in doses significantly exceeding the recommended ones, due to the possible absorption of the active substances of the preparation, attention should be paid to symptoms indicating nephro- and / or ototoxic reactions, especially in patients with trophic ulcers.

Treatment: symptomatic therapy.

Storage conditions

Powder - at a temperature not exceeding 25 ° C in its original packaging; ointment - at a temperature not higher than 25 ° C. Keep out of the reach of children.